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Donor-specific blood transfusion (DST) can lead to significant prolongation of allograft 
survival in experimental animal models and sometimes human recipients of solid organs. 
The mechanisms responsible for the beneficial effect on graft survival have been a topic 
of research and debate for decades and are not yet fully elucidated. Once we discover 
how the details of the mechanisms involved are linked, we could be within reach of 
a procedure making it possible to establish donor-specific tolerance with minimal or 
no immunosuppressive medication. Today, it is well established that CD4+Foxp3+ 
regulatory T cells (Tregs) are indispensable for maintaining immunological self-tolerance. 
A large number of animal studies have also shown that Tregs are essential for establishing 
and maintaining transplantation tolerance. In this paper, we present a hypothesis of one 
H2-haplotype-matched DST-induced transplantation tolerance (in mice). The formulated 
hypothesis is based on a re-interpretation of data from an immunogenetic experiment 
published by Niimi and colleagues in 2000. It is of importance that the naïve recipient 
mice in this study were never immunosuppressed and were therefore fully immune 
competent during the course of tolerance induction. Based on the immunological 
status of the recipients, we suggest that one H2-haplotype-matched self-specific Tregs 
derived from the transfusion blood can be activated and multiply in the host by binding to 
antigen-presenting cells presenting allopeptides in their major histocompatibility complex 
(MHC) class II (MHC-II). We also suggest that the endothelial and epithelial cells within 
the solid organ allograft upregulate the expression of MHC-II and attract the expanded 
Treg population to suppress inflammation within the graft. We further suggest that this 
biological process, here termed MHC-II recruitment, is a vital survival mechanism for 
organs (or the organism in general) when attacked by an immune system.
Keywords: tregs, indirect alloantigen presentation, direct alloantigen presentation, MHC-ii recruitment, dst, 
transplantation tolerance, haplotype-matched, self-tolerance
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introdUCtion
Today, transplantation tolerance in humans who receive an organ 
from a genetically disparate donor can very rarely be achieved 
without life-long administration of immunosuppressive therapy. 
While the current, non-specific immunosuppressive drugs are 
very good at inducing short-term graft survival, the impact on 
long-term engraftment has remained unchanged because most 
of the patients lose their transplants due to chronic rejection. 
Furthermore, due to general suppression of the immune system, 
the patients are exposed to a higher risk of infections and develop-
ing cancer. Therefore, the ultimate goal is to find a way to induce 
permanent donor-specific tolerance (1, 2).
Long-term alloantigen-specific transplantation tolerance of 
solid organs can easily be induced in rodents without continuous 
supply of immunosuppressants (3). Although the many success-
ful approaches in experimental animal models have failed when 
attempted in humans (4, 5), there are cases of drug-free humans 
carrying well-tolerated organs, such as kidneys and livers, from 
genetically disparate donors (6, 7). These rare cases of spontaneous 
tolerance (also termed operational tolerance) to a foreign organ 
provide hope that transplantation tolerance with no or minimal 
immune-suppressive medication can be achieved in humans.
A widely used strategy to induce long-term transplantation 
tolerance in experimental animal models is to introduce the organ 
recipient to alloantigens in the form of blood transfusion before 
transplantation (8). Multiple blood transfusions before transplan-
tation have also been shown to prolong kidney graft survival in 
humans and became a widely used strategy in the 1970s (9–11). 
However, the procedure may also sensitize the recipient to donor 
antigens. Therefore, following the development of highly efficient 
immune suppressive drugs in the 1980s, deliberate pretransplant 
blood transfusion has been either abolished or abandoned in 
virtually every hospital worldwide (12).
Sharing of a HLA/H2 haplotype between the recipient and 
blood donor in both humans and experimental animal models is 
associated with prolongation of graft survival. The effect is further 
optimized when the haplotype shared blood is donor specific, i.e., 
taken from the organ donor [donor-specific blood transfusion 
(DST)] (13–15).
The mechanisms responsible for DST-induced unresponsive-
ness are not fully understood. However, many experimental 
studies in animals indicate that perhaps the most powerful 
mechanism involved in prolongation of allograft survival is the 
suppressor function of Foxp3 CD4+CD25+ regulatory T cells 
(Tregs). Tregs are also found to be indispensable for maintaining 
peripheral self-tolerance. How DST may induce Tregs has been 
intensively studied for decades.
One central issue is whether donor-derived leukocytes are 
actively involved in inducing transplantation tolerance, and if 
so, how and to what extent. In this paper, we re-interpret an 
immunogenetic experiment conducted 17  years ago by Niimi 
et  al., and we present a hypothesis that suggests that actively 
involved donor blood-derived Tregs and the donor organ itself 
are crucial for the prolongation of the allograft survival achieved 
in their study.
CUrrent HypotHesis on 
aLLoantiGen-indUCed 
transpLantation toLeranCe
Donor cells from variable immune lineages may enter the recipi-
ent via the donor organ as “passenger cells” and pretransplanted 
donor blood. In the early 1990s, Thomas E. Starzl and his colleagues 
proposed a model of microchimerism and transplantation toler-
ance. According to this model, allograft acceptance is the effect of 
a balanced double immune reaction between donor and recipient 
cells, which is comparable to a mutual graft-versus-host/host-
versus-graft reaction, and causes reciprocal clonal exhaustion. 
Although the reaction eventually attenuates, it remains at a low 
level and keeps a dangerous increase of either of the two reac-
tions in check. The persistence of microchimeric cells is therefore 
considered to be a prerequisite for long-term allograft survival in 
this model (16).
In support of this hypothesis, donor leukocytes in the recy-
cling lymphoid pool of the host have been identified as important 
for inducing response reduction in experimental studies with 
animals (17).
Hypotheses that consider donor leukocytes as active par-
ticipants in tolerance induction have been challenged by other 
studies showing, for example, that reduced immunogenicity can 
be obtained if passenger cells are removed from the transplant 
(18). Additionally, there is strong evidence that the pathway of 
indirectly presented allopeptides [i.e., allopeptides that are pre-
sented by host antigen-presenting cells (APCs)] is used by Tregs 
for immune regulation (19–21). Microchimeric cells are therefore 
assumed to function mainly as a depot for alloantigens for the 
recipient immune system (20).
Data from non-immunosuppressed human recipients of one 
HLA-DR-shared pretransplant blood transfusion has spawned 
one of the latest models on the subject.
The data showed that these recipients had a reduction in 
acute rejection episodes compared to those patients who also 
received antithymocyte globulin as induction therapy (22). In 
accordance with current understanding, it is suggested that 
Tregs and effector T cells may be responsible for a substantial 
part of the unresponsiveness toward the donor organ, and fur-
ther that allospecific effector T cells pick up allopeptides from 
the transplanted organ and present them in their HLA class 
II molecules. The HLA class II/allopeptide complex may then 
serve as a specific target for Tregs induced by the donor blood. 
It is further suggested that when binding to the effector T-cells, 
Tregs cause cell lysis. This hypothesis is supported by a study 
of in  vitro-generated CD4+CD25+ T cell clones that showed 
that these cells lysed autologous cytotoxic T cells as long as the 
proper allopeptide was presented in the context of self-major his-
tocompatibility complex class II (MHC-II) (23). Recognition of 
MHC/allopeptide complexes by the blood transfusion-induced 
Tregs presupposes that blood and organ donor share one or more 
alloantigens and that these shared alloantigens are mismatched 
to the recipient.
Unfortunately, this model does not explain allotolerance in 
mice because mice T-cells do not produce MHC-II. Therefore, 
3Mohr Gregoriussen and Bohr Transfer of Self-tolerance from a Donor to an Organ Recipient
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 9
a different model is required to explain similar phenomena that 
occur in mice.
FeatUres oF treGs WHiCH are 
reLeVant to oUr HypotHesis
The discovery by Sakaguchi et al. in 1995 that a subset within 
the CD4+ T cell population that expresses CD25 are responsible 
for maintaining immunological self-tolerance in mice (24) trig-
gered enormous research activity on the subject. Subsequently, 
attention was further focused on this T-cell subset with the 
discovery of Foxp3 (forkhead box P3), a transcription factor 
that has proven to be a driving force for the development of 
Tregs in both mice and humans. Today, it is well established 
that Tregs are specialized for immune suppression of T-cell-
induced autoimmune responses. It is also well established 
that Tregs play a fundamental role in immune suppression of 
responses toward non-self-antigens such as allografts in many 
different animal models. The role of Tregs in immune tolerance 
has been extensively reviewed elsewhere (5, 25). The majority 
of Tregs that populate the peripheral lymphocyte pool develop 
in the thymus (tTregs or nTregs). Unlike conventional T cells, 
tTregs are positively selected by recognition of self-antigens, 
including peripheral tissue-specific antigenic peptides driven 
by AIRE on medullary thymic epithelial cells (26, 27).
Since tTregs are biased toward self-antigens, they are inter-
preted as crucial for maintaining peripheral immunological 
self-tolerance (28). Tregs may also be induced in the periphery 
(pTregs) or generated in  vitro (iTregs) from the naïve CD4+ 
T  cells population when encountering MHC/peptide com-
plexes on dendritic cells in tolerogenic environments, such as 
in the presence of TGF-β and interleukine-2 (IL-2) (29–34); i/p 
Tregs have been extensively reviewed in Ref. (35). In healthy 
individuals, pTregs are mainly located in mucosal surfaces such 
as in the gut and lungs where they control local inflammation 
(36). Tregs that recognize non-self-antigens are assumed to 
hold real promise for inducing specific tolerance to foreign 
graft antigens (28, 37).
Regulatory T cells may lose their suppressive activity or take 
on an effector phenotype. The longevity and stability of Tregs are 
associated with high expression of Foxp3. Foxp3 promotes the 
expression T-cell activation markers such as CTLA-4 and CD25, 
while it may inhibit the expression of IL-2 (38, 39). The stability 
of Foxp3 expression can be determined by the demethylation 
status of a conserved GpG-rich intronic region within the foxp3-
locus upstream of exon-1, also termed TSDR (40). For tTregs, 
the expression of Foxp3 is already initiated during early Treg 
development as Tregs pass through thymic medulla. Although 
Tregs that leave the thymus may not display a fully demethylated 
TSDR, experimental studies in mice suggest that commitment to 
a stable Treg lineage is established during early thymic develop-
ment (5, 41). It has also been shown that a substantial portion of 
tTregs that leave the thymus are in an antigen-primed stage and 
ready to regulate (25, 42).
Animal studies have shown that the intrathymic expression 
of Foxp3 and the further development of nTreg in the periphery 
as well as maintenance of the Treg linage are dependent on 
antigen-specific TCR signaling (43–45). Since tTregs constantly 
meet self-antigens in the periphery, they are considered as a 
more stable Treg line than pTregs which will lack sufficient TCR 
stimulus once the foreign antigen is eliminated (5).
Studies on CD62L+ (naïve) Tregs show that they proliferate 
vigorously in vivo upon antigen-specific stimulation and in the 
presence of IL-2, and die after exerting their suppressive activity. 
The life cycle of Tregs is interpreted as crucial for maintaining 
immune homeostasis (25, 46, 47). An increasing number of 
studies in humans and mice suggest that Tregs are distributed 
throughout non-lymphoid tissues where they are active in sup-
pression of inflammatory responses (33, 48). It has also been 
demonstrated that memory-like Treg take up residence in the tar-
get tissue after resolution of an inflammatory response. Moreover, 
these Tregs were primed to suppress a subsequent autoimmune 
response when the self-antigen was re-expressed by the inflamed 
tissue (49).
In line with this discovery, Tregs have been isolated from 
tolerated skin allografts in mice (50). In vitro studies have dem-
onstrated that Tregs can regulate immune responses on multiple 
levels and via several different mechanisms. For example, they 
can inhibit activation and function of APCs and produce immu-
noregulatory cytokines, such as TGF-β and IL-10, which act 
directly on effector T cells by impeding their priming and effec-
tor function (51). Tregs can also cause cytotoxic T-cell death by 
FasL/fas-mediated apoptosis (52). The regulatory mechanisms of 
Tregs have been reviewed by Povoleri et al. with references to the 
original literature (32). Another important suppressor function 
of Tregs is the ability to cause “linked” or “bystander” suppression 
of a population of effector T cells with specificity for a different 
antigen and to render these immunocompetent T cells tolerant 
over time. Furthermore, these tolerant cells might again confer 
tolerance to T cells that recognize a third-party antigen. This 
phenomenon is termed “infectious tolerance.” The chain reaction 
of tolerance induction requires that Tregs and T cells as well as 
the various alloantigenic peptides are attached to the same APC 
(13, 53, 54). The phenomena of linked suppression and infectious 
tolerance have been reviewed by Lechler et al. (55).
Although antigen-specific signaling via TCRs is important for 
Treg priming and function, recent studies in mice have shown 
that Tregs (that can regulate both direct and indirect presenta-
tion pathways) are needed to induce indefinite transplantation 
tolerance (29, 56). This clearly suggests that prevention of chronic 
rejection favors a persistent homogeneity between the direct and 
indirect pathway of alloantigen presentation/recognition, and 
example being that the recipient and donor share a HLA-DR/
MHC-class II molecule or a haplotype.
phenomena of allograft survival from an 
immunogenetic study by niimi et al.
Much of our understanding of the mechanisms involved in 
induced transplantation tolerance is derived from studies in 
mice. We know that there are significant differences between 
the immune system of a naïve, often genetically and immu-
nologically altered, mouse model and an adult human being, 
who has been exposed to several infections and vaccines 
throughout life. Yet, these studies are a rich source of ideas 
4Mohr Gregoriussen and Bohr Transfer of Self-tolerance from a Donor to an Organ Recipient
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 9
about some fundamental principles of immune regulation and 
how the mechanisms involved may be manipulated/adjusted 
according to requirements (13). There are two main reasons 
why we have chosen to analyze the phenomena that occur 
in this study. (1) Through its examination of the impact of 
organ donor MHC type and its relationship to blood donor 
and recipient MHC type on prolongation of allograft survival, 
this study takes into account all three parties involved—the 
recipient, the blood donor, and the organ donor. (2) Unlike 
the majority of experiments on tolerance, the recipients in this 
study were at no time immune suppressed. Thus, the immune 
status of the recipients was “active” at the time of transfusion 
and during the initial stage of tolerance induction. Therefore, 
interference of artificially forced immune phenomena such as 
antibody-induced clonal anergy can be ruled out. On the other 
hand, this minimally manipulated experiment may allow other 
mechanisms to become more apparent.
In the Niimi experiment, recipient (F1) mice were transfused 
with one haplotype-matched or fully mismatched donor blood 
7 days before transplantation. The recipient mice were then trans-
planted with a heart of different F1 mice with which they shared 
one haplotype (groups I, II, IV, V, and VI) or none (groups III and 
VII). All combinations are illustrated in Figure 1.
Two sets of experiments with different blood donors were 
conducted to ensure that the effects of pretransplant blood trans-
fusion were not restricted to a specific strain combination. The 
results were similar.
Optimal prolongation of graft survival was achieved in 
recipient mice which received one haplotype-matched DST 
(approximately 40% at day 100) (I). Graft survival at day 100 was 
also obtained in 10% of the recipients that shared one haplotype 
with the blood donor and the mismatched haplotype with the 
organ donor (IV). The survival curve in this group was quite 
similar to that in which the recipient and both donors shared the 
same haplotype but were mismatched for the other haplotype 
(II). However, in the latter test group, all hearts had been rejected 
by day 70. Recipients transfused with homozygous blood from 
a mismatched donor obtained moderate graft prolongation (all 
rejected by day 38) (V). The graft was rejected immediately if the 
blood was derived from a haplotype-matched homozygous donor 
(VI). Prolongation of graft survival was also not achieved with 
fully mismatched DST (VII).
In pilot studies with purified CD4+ T cells from mice after 
haplotype-matched blood transfusion, Niimi et  al. found that 
these cells had the ability to downregulate donor-specific CTL 
responses in a specific way. This finding indicates that allospecific 
Tregs had been induced by the blood transfusion and that these 
Tregs were involved in prolongation of graft survival.
According to Niimi et  al., graft survival induced by the 
matched DST is probably due to priming of host T cells that rec-
ognize allopeptides presented by self(shared)-MHC indirectly 
on recipient APC and directly on donor APCs. However, since 
graft survival was also prolonged in combinations where the 
blood and organ donor shared only the mismatched haplotypes 
(IV and V), Niimi et al. suggest that presentation of allopeptides 
by recipient (self)-APCs is the essential pathway for tolerance 
induction.
Although indirect alloantigen recognition may have been 
essential to tolerance induction during the pretreatment regimen, 
the hypothetical-induced Tregs had to be reactivated by the trans-
planted organ for graft prolongation to occur. According to Niimi 
et al., this explains why the hearts in group III were all immediately 
rejected. In their own words: “… the organ did not have a recipient 
haplotype and was therefore not able to present the allopeptide.”
With regard to prolongation of graft survival in group II where 
the blood and organ donor share a recipient haplotype while 
being mismatched for the other, Niimi et al. suggest that the toler-
ance achieved is due to cross-reactivity or sharing of allopeptides 
between the mismatched haplotypes (haplotypes B and C).
Several mechanisms may have contributed to the prolonga-
tion of graft survival obtained in the Niimi et al. study. It is, for 
example, well known that alloreactive T cells anergize or are 
deleted when reacting with donor-derived allopeptides or allo-
MHC complexes in non-inflammatory transplantation settings 
(57). Although such passive immunological conditions are 
unlikely to last long, they may create favorable immunological 
situations for the establishment of other more permanent and 
active regulatory mechanisms, such as the induction/conversion 
of Tregs. However, it can be questioned whether this “tolerogenic” 
immunological situation would have been crucial for the induc-
tion of tolerance in mice that were fully immune competent and 
never immunosuppressed.
The direct pathway of allorecognition is primarily associated 
with acute graft rejection (58). In experiments where tolerance is 
induced without the use of immunosuppressants, conventional 
effector T cells would be expected to be primed to reject the donor 
organ instead of being converted into Tregs. The hypothesis 
presented in this paper  seeks an explanation for how Tregs in 
the Niimi experiment may be induced and cause prolongation of 
graft survival in an inflammatory setting.
donor tregs and MHC-ii  
recruitment—transfer of self-tolerance 
to the organ recipient
All mice in the Niimi experiment were naive (i.e., immuno-
logically inexperienced). Therefore, we also find it reasonable to 
assume that a substantial portion of the Tregs were self-specific 
tTregs, positively selected in the thymus upon encountering 
tissue-specific antigens before entering the periphery (51, 59). 
Because there is access to constant sources of self-antigens, self-
specific tTregs may be in a more mature developmental stage than 
Tregs with allospecific TCRs (5). Based on these assumptions, we 
hypothesize that
 I. Whole live blood contains functional self-specific Tregs, 
which are transferred to the recipient by blood transfusion. 
These self-specific donor-Tregs can be activated (if this is not 
already the case) and proliferate via the indirect pathway of 
antigen recognition/presentation, i.e., recipient APCs, if (a) 
the donor and recipient have a sufficient match of major 
histocompatibility complex (MHC) classes I and II, for exam-
ple, share one haplotype and (b) the recipient APCs present 
the donor-derived peptide that is recognized naturally by 
the donor-derived Treg and the indirect antigen-presenting 
FiGUre 1 | an overview of self-major histocompatibility complex class ii (MHC-ii)/peptide share between the recipient and blood donor and the 
possibility for induction of regulatory t cells (tregs) which can recognize the same peptide/MHC complex on host and donor antigen-presenting 
cells (apCs) in the study by niimi et al. All F1 recipient mice (DxA) were transfused with matched/mismatched blood prior to transplantation. One week later, the 
recipients were transplanted with one haplotype-matched or fully mismatched hearts. Allograft survival was optimal in recipients of one haplotype-matched 
donor-specific blood transfusion (DST) (Grp I), while the graft was rejected immediately in recipients transfused with fully mismatched DST (in Grp VII). In Grp I, there 
is the potential for activation of Tregs which can bind to 50% of the MHC-II/allopeptide complexes on the donor organ (AxB) (blue spots in the bottom row). 
Generation of Tregs with similar binding characteristics may also occur in Grp IV and V; only in these two cases, the donor-Tregs will either not recognize MHC/
peptide complexes on the donor organ (Grp IV) or the recipient APC (Grp V). The 10% graft survival by day 100 was achieved in Grp IV, while all hearts had been 
rejected by day 38 in Grp V. Prolongation of graft survival achieved in Grp IV and V, and in particular the different outcomes in these two groups indicate that the 
indirect pathway of alloantigen presentation plays a pivotal role in tolerance induction—i.e., that the mismatched peptide (b) must be presented by host APC (A or 
D). How can the different outcomes then be explained? Passenger cells such as donor DCs have mainly been associated with acute rejection episodes. However, 
the more successful outcome of graft survival in Grp I seems to be linked to the blood donor after all. As suggested by our hypothesis, blood donor-derived 
self-specific tTregs may be responsible. These hypothetical tTregs can bind to both pathways of allo-antigen presentation (e.g., peptide b presented by MHC-A on 
host and donor APCs) and may succeed in disarming the initiation of a deleterious alloresponse. This tolerogenic situation may again create favorable conditions for 
the formation of a more solid network consisting of several tolerance-promoting mechanisms. Self-specific tTregs derived from H2/haplotype-matched donor blood 
may also explain the different outcomes in Grp IV and V by inducing linked suppression and infectious tolerance against the graft via host APCs (Grp IV). 
Prolongation of graft survival in Grp II may be due to some allopeptides derived from the “b” and “c” genetic backgrounds being identical. Furthermore, self-specific 
(A/a) donor and recipient tTregs may also contribute to the tolerance achieved in this group. As the results in Grp VI indicate, these hypothetical tTregs are not 
sufficient to induce tolerance on their own in this experiment setting. One explanation may be that there is a need for an inflammatory condition to activate the 
regulatory system. All values are our own estimation based on a graphical presentation in the article of Niimi et al. F1 combinations: A, C57BL/10; B, BALB/c; C, 
SJL; D, CBA, “a, b, c, and d” represent self-peptides derived from the inbred strains designated as A, B, C, and D, respectively. Grp, group; †, allograft rejection; 
⚫, self-MHC/peptide complexes on host APC or the solid donor organ that may be recognized by self-specific donor Tregs.
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profile (MHC/peptide profile) is functionally identical to the 
immunological self of the blood donor, i.e., that at least some 
self-peptide/MHC complexes are identical in the recipient 
and blood donor, the antigenic background on which that 
these blood donor-derived Tregs have been selected on.
As illustrated in Figure 2, our model suggests that self-specific 
donor tTregs recognize MHC-II/allopeptide complexes on host 
APCs that are functionally identical to the immunological self 
of the donor. There is a possibility that the transferred self-
specific donor Tregs would be more easily activated by antigenic 
stimuli because they are positively selected in the thymus and are 
probably at a more advanced stage of development than naive 
allospecific recipient T cells. Additionally, in  vitro studies have 
shown that Foxp3 Tregs can physically out-compete non-Tregs 
in aggregating around APCs (52).
FiGUre 2 | transplantation tolerance by donor ttregs and major histocompatibility complex class ii (MHC-ii) recruitment. A simplified presentation of 
the hypothesis of one haplotype-matched donor-specific blood transfusion-induced allotolerance in the study by Niimi et al. The process is divided into two main 
phases: (1) what may happen in the time period between blood transfusion and transplantation (i) and (ii) and (2) after transplantation (iii). Donor-derived self-specific 
tTregs become (i) activated and (ii) proliferate by recognizing self-MHC-II/allopeptide complexes on host antigen-presenting cells that are functionally identical to the 
antigenic background they were selected on in thymus. During this preliminary phase of tolerance induction, activated donor tTregs may induce linked suppression 
and infectious tolerance before transplantation (not shown). These regulatory T cells (Tregs) may be reactivated after transplantation when encountering self-MHC-II/
peptide complexes on the solid organ allograft (iii). According to the hypothesis, the enhancement of transplantation tolerance in non-immune-suppressed recipients 
is dependent on MHC-II recruitment (upregulation of MHC-II expression) by epithelial and endothelial cells within the solid organ allograft. As suggested by the 
hypothesis downregulation of the alloresponse may be effectuated by two different pathways: (a) recognition of intact donor organ MHC-II/peptide complexes 
which are taken up and presented by rDCs, e.g., via trogocytosis, shed MHC-II/peptide complexes (not shown) or fusion with exosomes, and (B) by binding directly 
to the allograft. In both cases (pathways A and B), donor-Tregs may physically out-compete naive alloreactive T cells, suppress or kill neighboring donor reactive 
effector T cells, or convert them into secondary regulatory cells (induce infectious tolerance). The regulatory effector mechanisms included in the figure, IL-10 and 
TGF-β in pathway A (pictured as small black dots) and FasL/Fas in pathway B, serve only as a few examples and are randomly placed. So are the recipient effector 
T cells. Further, the effector mechanisms may be operating together in each pathway. dnTreg, donor tTregs; dMHC, donor MHC; rMHC, recipient MHC; rTh, 
recipient Th; rDC, recipient DC.
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This situation could delay or even impair the establishment 
of a response against antigens from the blood donor and allow 
large-scale multiplication of donor Tregs before the organ is 
transplanted.
As indicated by the different outcomes of allograft survival 
in group I and, i.e., II and IV, the hypothetical multiplied self-
specific donor tTregs appear to be restricted to carrying out their 
full regulatory potential of responses against a genetic identical 
organ donor. We further hypothesize that
 II. As a vital part of the maintenance of immunological self-
tolerance, (a) responses directed against organs (either as a 
HVG-reaction or auto-reactive) cause the cells of the attacked 
organ (endothelial and epithelial cells) to produce or upregu-
late the production of MHC-II molecules. We have chosen 
to term the upregulation of MHC-II “MHC-II recruitment.” 
MHC-II recruitment allows for activated self-specific Tregs 
(and recipient Tregs with direct allospecificity) to bind 
specifically to the organ and downregulate immune responses 
at the site of inflammation. This self-protecting mechanism 
will be activated if or when the transplanted organ is attacked 
by the host immune system.
The specific acquired tolerance in recipients that were 
transfused with one haplotype-matched DST can be explained 
by MHC-II recruitment by the endothelial/epithelial cells of 
the transplanted organ. From here, two pathways, which are 
not mutually exclusive, can support Tregs in performing their 
memory function and maintaining allotolerance: (1) semi-direct 
recognition of MHC-II/peptide complexes transferred directly by 
epithelial cells to recipient DCs (rDCs) or by epithelial exosomes 
and membrane vesicles (60–62); (2) direct binding to cognate 
MHC-II/peptide complexes on the epithelial and endothelial 
cells. Both suggestions would give donor-Tregs the ability to 
suppress or kill bystander donor reactive effector T cells or even 
convert them into secondary regulatory cells (63). Conversion 
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and suppression of effector T cells by activated donor tTregs may 
already occur via rDCs before the donor organ is transplanted. 
The hypothetical induction of pTregs with specificity for a differ-
ent MHC-II/peptide combination (D/b) than that of the blood 
donor-derived tTregs can explain prolongation of graft survival 
in group IV.
The suggestion that MHC-II recruitment is essential for Tregs 
to achieve their full regulatory potential, both in transplantation 
tolerance and peripheral immunological self-tolerance, is con-
sistent with the following discoveries: (1) several studies have 
demonstrated that endothelial and epithelial cells in human 
transplants and in mice upregulate their production of MHC-II 
molecules (64–66). (2) In a colitis-induced mouse model, a 
strong correlation was found between IFN-γ-induced produc-
tion of MHC-II in intestinal epithelial cells and the protection 
of colitis (67). (3) It has recently been demonstrated that IFN-
γ-induced production of MHC-II in vascular endothelium in 
mice promotes Treg trafficking to the site of inflammation by 
specific antigen recognition of the endothelium. Furthermore, 
the influx of Tregs in this study did eventually result in a sig-
nificant decrease in the influx of effector T cells to the target 
tissue (68).
The attachment of Tregs to endothelial/epithelial MHC-II/
peptide complexes may even be a short cut to reactivation 
of Tregs (memory Tregs) as suggested by Niimi et  al. 17  years 
ago. Although activation of T lymphocytes is closely linked to 
professional APCs, recent studies have shown that hepatocytes 
from a transgenic mouse model, expressing stable MHC-II and 
featuring CD80, are able to activate CD4+ T cells. In this study, 
the epithelial activation of CD4+ T cells was not associated with 
autoimmune reactions (69). Additionally, it has recently been 
suggested by Kambayashi and Laufer that the production of 
MHC-II in non-hematopoietic cells may contribute to tolerance 
by stimulating Tregs (70). The latter may explain why spontane-
ous tolerance toward liver transplants is more frequent compared 
to other solid organ allografts (71).
Although our hypothesis is about transplantation tolerance 
induced by donor tTregs, recipients of one haplotype-matched 
allografts may, like the donor, harbor self-specific tTregs that 
recognize and bind self-MHC-II/peptide complexes on the 
donor organ. These hypothetical recipient tTregs may have 
been a contributing factor to prolongation of graft survival in 
recipients that were not tolerated for the mismatched antigen in 
the donor organ, as in group II. However, since tolerance was 
not achieved with matched pretransplanted homozygous donor 
blood (A in group VI), recipient and donor tTregs appear to 
be incapable of inducing tolerance without the presence of 
an alloantigen, for example, allopeptides from shared minor 
antigens between the blood donor (haplotype B) and the organ 
donor (haplotype C) as indicated by the outcome in group II 
(Figure 1).
sUMMary and FUtUre perspeCtiVes
In this article, we have introduced a novel hypothesis on DST-
induced transplantation tolerance based on a re-interpretation 
of a 17-year-old immunogenetic study by Niimi et  al. (13). 
The animals in this study never received any immunosup-
pressive drug, which is unusual and excludes interference of 
artificially forced immune phenomena, such as antibody-induced 
clonal anergy. We find that such experiments facilitate the 
analysis and may allow other mechanisms to become more 
apparent.
Based on the immune status of the mice in the experiment 
of Niimi et al., two main suggestions have been presented in the 
hypothesis: (1) blood donor-derived self-specific tTregs can be 
(re)activated and multiplied by indirectly recognizing MHC/
peptide complexes on host APC that correspond to the antigenic 
background they have been selected on in thymus; (2) the trans-
planted organ upregulates endothelial/epithelial expression of 
MHC-II if or when the organ is attacked by the host immune 
system. It is further suggested that the multiplied donor tTregs 
suppress bystander allospecific T cells and may induce infectious 
tolerance by binding directly to the donor organ or semi-directly 
to professional host APCs.
This hypothesis is consistent with recent animal studies which 
have shown that for long-term transplantation tolerance to occur, 
there is a need for Tregs that recognize allopeptides presented by 
self-MHC-II on host and donor APCs.
Several studies have indicated that tTregs constitute a more 
stable and mature cell population than Tregs induced from the 
naïve T-cell pool. Therefore, approaches that focuses on self-
specific donor tTregs with specificity for self-peptides presented 
by shared MHC-II could be an attractive shortcut to prolongation 
of allograft survival because many apparently difficult steps in the 
generation of new Tregs from the naïve T cell pool may already 
have been completed. Yet, introduction of donor-specific antigens, 
such as donor blood and donor Tregs, prior to transplantation 
may increase the risk of immunizing the host.
According to our hypothesis, recipients of one haplotype-
matched allografts may, just like the donor, harbor self-specific 
tTregs that can recognize and bind to both pathways of alloan-
tigen presentation. Expansion of such recipient tTregs could 
minimize the risk of immunizing the host. This mechanism may 
have contributed the moderate prolongation of graft survival in 
group II. However, it is crucial to find out why tolerance was 
not induced with haplotype-matched homozygous donor blood 
(group VI).
To further support the hypothesis proposed in this manu-
script, it will be important to test experimentally the longevity 
of Tregs alive in the recipient and whether these Tregs are 
essential for tolerance induction. It is also important to test 
whether the transplanted organ upregulates the production of 
MHC-II and whether these donor MHC II/peptide complexes 
are transferred to recipient APCs/DCs. Finally, support of the 
hypothesis will also require testing of whether linked suppres-
sion and infectious tolerance occurs in the donor:recipient 
combination.
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